NASDAQ:CRSP

Crispr Therapeutics Stock News

etoro logo Buy CRSP
*Your capital is at risk
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri

3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030

10:02am, Monday, 02'nd May 2022 The Motley Fool
These stocks are losers now. But they could be huge winners over the next few years.
These stocks are losers now. But they could be huge winners over the next few years.

2 Biotech Stocks to Buy and Hold for 10 Years

01:05pm, Saturday, 30'th Apr 2022 The Motley Fool
These two companies have moved in opposite directions on the stock market so far this year, but now seem set to move up and to the right.
Upgrades According to Johnson Rice, the prior rating for RPC Inc (NYSE:RES) was changed from Hold to Accumulate. In the first quarter, RPC showed an EPS of $0.07, compared to $0.05 from the year-ago

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics

01:14pm, Thursday, 28'th Apr 2022 Benzinga
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0

These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge

01:18pm, Wednesday, 27'th Apr 2022 The Motley Fool
Make sure that you're aware of the risks before buying these promising growth stocks.

Crispr Therapeutics: Progress, Risk, And Reward

10:18am, Wednesday, 27'th Apr 2022
CRISPR Therapeutics continues to make progress in all of its development platforms. The company continues to confirm the filing date for CTX001.
Make sure that you're aware of the risks before buying these promising growth stocks.

3 Cathie Wood Stocks to Count on in Q2

06:45am, Tuesday, 26'th Apr 2022
These Cathie Wood Stocks have their risks but offer a massive upside potential ahead The post 3 Cathie Wood Stocks to Count on in Q2 appeared first on InvestorPlace. More From InvestorPlace Stock Prod

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

10:00pm, Friday, 22'nd Apr 2022 Zacks Investment Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $55.68, marking a +0.27% move from the previous day.

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

06:58pm, Friday, 22'nd Apr 2022 Zacks Investment Research
On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.

7 Potential Biotech Stocks Buyout Targets in 2022

08:10am, Thursday, 21'st Apr 2022
Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl

3 Ominous Reasons to Avoid This Biotech Pioneer

10:20am, Tuesday, 19'th Apr 2022 The Motley Fool
They point to trouble for investors counting on a rebound.

3 Ominous Reasons to Avoid This Biotech Pioneer

06:20am, Tuesday, 19'th Apr 2022
They point to trouble for investors counting on a rebound.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE